Middle East Molecular Diagnostics Market - Country Analysis: Focus on Product, Testing Location, Technology, Application, End User, and Country Data - Analysis and Forecast, 2021-2031
Description
Middle East Molecular Diagnostics Market - Country Analysis: Focus on Product, Testing Location, Technology, Application, End User, and Country Data - Analysis and Forecast, 2021-2031
Middle East Molecular Diagnostics Market Industry Overview
The Middle East molecular diagnostics market is projected to reach $1,017.7 million by 2031 from $493.1 million in 2020, at a CAGR of 6.72% during the forecast period 2021-2031. The growth in the Middle East molecular diagnostics market is expected to be driven by factors such as the increasing prevalence of infectious diseases and various types of cancer in the Middle East, rising awareness of personalized medicine and its acceptance, coupled with the significant number of funding for executing R&D in Middle East region.
Market Lifecycle Stage
Diagnostics is a well-developed market with an integral part of medical decision-making -aid in acquiring information for a wide range of treatment dissemination, accentuating their criticality in healthcare. Molecular diagnostics has a critical role in the precision medicine approach, as it ensures the safe and effective application of targeted therapeutics. Most of the players in the Middle East molecular diagnostics market offer products encompassing the kits and reagents, instruments, and software categories.
Increasing investments in the R&D for molecular diagnostics is one of the major opportunities in the Middle East molecular diagnostics market. Several diagnostics and pharmaceutical companies are working collaboratively to develop next-generation sequencing (NGS), polymerase chain reaction (PCR), immunohistochemistry (IHC), in-situ hybridization (ISH), microarray, nucleic acid amplification-, or mass spectrometry-based molecular diagnostics for the applications in several disease indications in order to enable efficient diagnosis, treatment selection, dosage selection, and treatment monitoring.
Impact
Several techniques are employed in modern molecular diagnostics to detect and quantify specific DNA or RNA sequences, as well as proteins. Some of these additional technologies are described briefly below:
The current Middle East molecular diagnostics market comprises software, instruments, and consumables. It has been noticed that there has been a reduction in the capacity or shutdowns of laboratories and other research institutions, that have led to reduced usage of instruments, consumables, and software related to research. Overall, the impact of COVID-19 on the Middle East molecular diagnostics market size has been low-moderate. Some of the market players have reported a slight decline in sales. However, financials are already on their way to recovery. The decline in revenues was mostly a result of the initial phases of the COVID-19 pandemic, which comprised complete lockdowns across countries and major cities, thus interrupting the supply chain. The timeline of impact spanned the end of the first quarter and the second quarter of 2020 for most of the key markets across the Middle East. However, the pandemic has played a key role in enhancing the growth prospects of molecular diagnostics and is expected to indirectly aid in improving the market growth outlook.
Market Segmentation
Segmentation 1: by Product
Segmentation 2: by Testing Location
Segmentation 3: by Technology
Segmentation 4: by Application
Segmentation 5: by End User
Segmentation 6: by Country
Recent Developments in Middle East Molecular Diagnostics Market
Following are the demand drivers for the Middle East Molecular Diagnostics Market:
Product/Innovation Strategy: Major manufacturers of the Middle East molecular diagnostic market, along with the service providers, are actively involved in undertaking significant business strategies to translate success in research and development into the commercial clinical setting.
Growth/Marketing Strategy: Owing to the explosion of massively parallel sequencing and its applications, all areas of medicine have been affected, particularly molecular diagnostics. PCR has gradually evolved from gel analysis to real-time PCR to, more recently, digital PCR. In digital PCR, amplification of individual targets is done in picolitre to nanoliter volumes, and instead of standard curves or internal controls, statistics are employed to calculate target concentrations. Genome-wide studies have gone beyond unknown expeditions, and disease association studies that use the expression, single nucleotide polymorphism, and copy number microarrays have identified useful markers that have been reduced to practical molecular tests. Big data needs have resulted in new bioinformatics tools that continue to evolve rapidly.
Competitive Strategy: Key players in the Middle East molecular diagnostics market analyzed and profiled in the study have been involved as the Middle East molecular diagnostics-based product manufacturers that provide software and molecular diagnostic services. Moreover, a detailed competitive benchmarking of the players operating in the Middle East molecular diagnostics market has been done to help the reader understand how players stack against each other, presenting a clear market landscape. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the market.
Key Market Players and Competition Synopsis
The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and market penetration.
Some of the prominent names established in this market are:
*PDF email from publisher allows for 1-3 users, with permission to print*
Middle East Molecular Diagnostics Market Industry Overview
The Middle East molecular diagnostics market is projected to reach $1,017.7 million by 2031 from $493.1 million in 2020, at a CAGR of 6.72% during the forecast period 2021-2031. The growth in the Middle East molecular diagnostics market is expected to be driven by factors such as the increasing prevalence of infectious diseases and various types of cancer in the Middle East, rising awareness of personalized medicine and its acceptance, coupled with the significant number of funding for executing R&D in Middle East region.
Market Lifecycle Stage
Diagnostics is a well-developed market with an integral part of medical decision-making -aid in acquiring information for a wide range of treatment dissemination, accentuating their criticality in healthcare. Molecular diagnostics has a critical role in the precision medicine approach, as it ensures the safe and effective application of targeted therapeutics. Most of the players in the Middle East molecular diagnostics market offer products encompassing the kits and reagents, instruments, and software categories.
Increasing investments in the R&D for molecular diagnostics is one of the major opportunities in the Middle East molecular diagnostics market. Several diagnostics and pharmaceutical companies are working collaboratively to develop next-generation sequencing (NGS), polymerase chain reaction (PCR), immunohistochemistry (IHC), in-situ hybridization (ISH), microarray, nucleic acid amplification-, or mass spectrometry-based molecular diagnostics for the applications in several disease indications in order to enable efficient diagnosis, treatment selection, dosage selection, and treatment monitoring.
Impact
Several techniques are employed in modern molecular diagnostics to detect and quantify specific DNA or RNA sequences, as well as proteins. Some of these additional technologies are described briefly below:
- Immunohistochemistry (IHC): IHC is the utilization of monoclonal and polyclonal antibodies for the detection of specific antigens in tissue sections.
- In Situ Hybridization (ISH or FISH): This is a technique that unwinds DNA or RNA in the sample and employs a labeled DNA or RNA strand (probe), which hybridizes with the complementary sequence on an unwound strand (target).
- Polymerase Chain Reaction (PCR): Polymerase chain reaction (PCR) allows researchers to amplify a small amount of DNA to quantities that can be used for analysis. PCR has ushered in a golden era in molecular diagnostics.
- Sequencing (CE, NGS): The sequencing allows the mapping of the entire sequence of the nucleotides that comprise a strand of DNA. As of 2020, sequencing can be achieved through capillary electrophoresis (CE) or through multiple next-generation sequencing (NGS) methods.
The current Middle East molecular diagnostics market comprises software, instruments, and consumables. It has been noticed that there has been a reduction in the capacity or shutdowns of laboratories and other research institutions, that have led to reduced usage of instruments, consumables, and software related to research. Overall, the impact of COVID-19 on the Middle East molecular diagnostics market size has been low-moderate. Some of the market players have reported a slight decline in sales. However, financials are already on their way to recovery. The decline in revenues was mostly a result of the initial phases of the COVID-19 pandemic, which comprised complete lockdowns across countries and major cities, thus interrupting the supply chain. The timeline of impact spanned the end of the first quarter and the second quarter of 2020 for most of the key markets across the Middle East. However, the pandemic has played a key role in enhancing the growth prospects of molecular diagnostics and is expected to indirectly aid in improving the market growth outlook.
Market Segmentation
Segmentation 1: by Product
- Systems
- Kits and Consumables
- Software and Other Products
Segmentation 2: by Testing Location
- Laboratory Testing
- Point-of-Care Testing
Segmentation 3: by Technology
- Polymerase Chain Reaction (PCR)
- Next-Generation Sequencing (NGS)
- Isothermal Nucleic Acid Amplification Technology (INAAT)
- Microarray
- In-Situ Hybridization (ISH)
- Immunohistochemistry (IHC)
- Other Technologies
Segmentation 4: by Application
- Core Molecular Diagnostics
- Reproductive Genetics
- Companion Diagnostics
- Liquid Biopsy
- Others
Segmentation 5: by End User
- Hospitals
- Diagnostic Centres
- Outpatient Clinics/General Practitioners
- Research Laboratories
- Others
Segmentation 6: by Country
- Kingdom of Saudi Arabia (K.S.A.)
- Israel
- United Arab Emirates (U.A.E.)
- Egypt
- Iran
- Qatar
- Other Countries
Recent Developments in Middle East Molecular Diagnostics Market
- In January 2022, Abbott showcased its life-changing diagnostic tools and medical devices product portfolio for point-of-care testing (POCT) that helped COVID-19, diabetes, and cardiovascular disease patients at MEDLAB Middle East.
- In June 2021, biomeruix launched EPISEQ SARS-COV-2 to identify SARS-CoV-2 variants using samples from COVID-19 positive patients.
- In 2021, the BD. company declared the approval of the BD Veritor At-Home COVID-19 Test for the detection of SARS-CoV-2 with definitive digital results at home.
- In 2020, Bio-Rad Laboratories, Inc. partnered with Seegene, Inc., a Middle East leader in multiplex molecular diagnostics, for the commercialization and clinical development of molecular diagnostic products.
Following are the demand drivers for the Middle East Molecular Diagnostics Market:
- Increasing Prevalence of Infectious Diseases and Various Types of Cancer in the Middle East
- Increase in Awareness and Acceptance of Personalized Medicines in the Middle East
- Significant External Funding for Executing Research and Development Exercises
- Uncertain Reimbursement Scenario
- Lack of High-Complexity Testing Centers in the Middle East
Product/Innovation Strategy: Major manufacturers of the Middle East molecular diagnostic market, along with the service providers, are actively involved in undertaking significant business strategies to translate success in research and development into the commercial clinical setting.
Growth/Marketing Strategy: Owing to the explosion of massively parallel sequencing and its applications, all areas of medicine have been affected, particularly molecular diagnostics. PCR has gradually evolved from gel analysis to real-time PCR to, more recently, digital PCR. In digital PCR, amplification of individual targets is done in picolitre to nanoliter volumes, and instead of standard curves or internal controls, statistics are employed to calculate target concentrations. Genome-wide studies have gone beyond unknown expeditions, and disease association studies that use the expression, single nucleotide polymorphism, and copy number microarrays have identified useful markers that have been reduced to practical molecular tests. Big data needs have resulted in new bioinformatics tools that continue to evolve rapidly.
Competitive Strategy: Key players in the Middle East molecular diagnostics market analyzed and profiled in the study have been involved as the Middle East molecular diagnostics-based product manufacturers that provide software and molecular diagnostic services. Moreover, a detailed competitive benchmarking of the players operating in the Middle East molecular diagnostics market has been done to help the reader understand how players stack against each other, presenting a clear market landscape. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the market.
Key Market Players and Competition Synopsis
The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and market penetration.
Some of the prominent names established in this market are:
- Abbott
- Agilent Technologies, Inc.
- bioMérieux SA
- BD
- Babirus Medical Equipment LLC
- Bio-Rad Laboratories, Inc.
- Danaher
- F. Hoffmann-La Roche Ltd.
- Guardant Health
- Illumina, Inc.
- QIAGEN N.V.
- Thermo Fisher Scientific Inc.
*PDF email from publisher allows for 1-3 users, with permission to print*
Table of Contents
179 Pages
- 1 Middle East Molecular Diagnostics Market
- 1.1 Product Definition
- 1.1.1 Inclusion and Exclusion
- 1.2 Market Overview
- 1.3 Historical Perspective
- 1.4 Significant Technologies
- 1.5 Classification of Molecular Diagnostics
- 1.6 Future Potential
- 2 Industry Insights
- 2.1 Patent Analysis
- 2.1.1 Patent Filing Trend
- 2.2 Legal Requirements
- 2.2.1 Legal Requirements and Framework in the U.S.
- 2.2.2 U.S. FDA Regulations
- 3 Competitive Landscape
- 3.1 Competitive Landscape
- 3.1.1 Acquisitions
- 3.1.2 Synergistic Activities
- 3.1.3 Product Launches and Upgradations
- 3.1.4 Business Expansion
- 4 Market Dynamics
- 4.1 Market Dynamics
- 4.1.1 Impact Analysis
- 4.1.2 Market Drivers
- 4.1.2.1 Increasing Prevalence of Infectious Diseases and Various Types of Cancer in the Middle East
- 4.1.2.2 Increase in Awareness and Acceptance of Personalized Medicines in the Middle East
- 4.1.2.3 Significant External Funding for Executing Research and Development Exercises
- 4.1.3 Market Restraints
- 4.1.3.1 Uncertain Reimbursement Scenario
- 4.1.3.2 Lack of High-Complexity Testing Centers in the Middle East
- 4.1.4 Market Opportunities
- 4.1.4.1 Massive Scope for Adoption of Molecular Diagnostics
- 4.1.4.2 Rise of Next-Generation Ultrasensitive Molecular Diagnostics
- 4.1.4.3 Novel Revenue Streams
- 4.2 COVID-19 Impact on Middle East Molecular Diagnostics Market
- 4.2.1 Impact on Market Size
- 4.2.2 Impact on Molecular Diagnostic Practices
- 5 Middle East Molecular Diagnostics Market, by Products, $Million, 2021 - 2031
- 5.1 Overview
- 5.1.1 Systems
- 5.1.2 Kits and Consumables
- 5.1.3 Software and Other Products
- 6 Middle East Molecular Diagnostics Market, by Testing Location, $Million, 2021 - 2031
- 6.1 Overview
- 6.1.1 Laboratory Testing
- 6.1.2 Point-of-Care Testing
- 7 Middle East Molecular Diagnostics Market, by Technology, $Million, 2021 - 2031
- 7.1 Overview
- 7.1.1 Polymerase Chain Reaction (PCR)
- 7.1.2 Next-Generation Sequencing
- 7.1.3 Isothermal Nucleic Acid Amplification Technology (INAAT)
- 7.1.4 Microarray
- 7.1.5 In-Situ Hybridization (ISH)
- 7.1.6 Immunohistochemistry (IHC)
- 7.1.7 Other Technologies
- 8 Middle East Molecular Diagnostics Market, by Application, $Million, 2021 - 2031
- 8.1 Overview
- 8.1.1 Core Molecular Diagnostics
- 8.1.2 Reproductive Genetics
- 8.1.3 Companion Diagnostics (CDx)
- 8.1.4 Liquid Biopsy
- 8.1.5 Other Applications
- 9 Middle East Molecular Diagnostics Market, by End User, $Million, 2021 - 2031
- 9.1 Overview
- 9.1.1 Hospitals
- 9.1.2 Diagnostic Centers
- 9.1.3 Out-Patient Clinics/General Practitioners
- 9.1.4 Research Laboratories
- 9.1.5 Other End Users
- 10 Middle East molecular diagnostics Market, by Country, $Million, 2020-2031
- 10.1 Overview
- 10.1.1 Kingdom of Saudi Arabia (KSA)
- 10.1.2 Israel
- 10.1.3 United Arab Emirates (U.A.E.)
- 10.1.4 Egypt
- 10.1.5 Iran
- 10.1.6 Qatar
- 10.1.7 Rest-of-the-Middle East
- 11 Market - Competitive Benchmarking & Company Profiles
- 11.1 Overview
- 11.2 Abbott.
- 11.2.1 Company Overview
- 11.2.2 Role of Abbott. in the Middle East Molecular Diagnostics Market
- 11.2.3 Key Competitors of the Company
- 11.2.4 Key Customers of the Company
- 11.2.5 Business Strategies
- 11.2.6 Financials
- 11.2.7 Key Insights about Financial Health of the Company
- 11.2.8 SWOT Analysis
- 11.3 Agilent Technologies, Inc.
- 11.3.1 Company Overview
- 11.3.2 Role of Agilent Technologies, Inc. in the Middle East Molecular Diagnostics Market
- 11.3.3 Key Competitors of the Company
- 11.3.4 Key Customers of the Company
- 11.3.5 Business Strategies
- 11.3.6 Corporate Strategies:
- 11.3.7 Financials
- 11.3.8 Key Insights about Financial of the Company
- 11.3.9 SWOT Analysis
- 11.4 bioMérieux SA
- 11.4.1 Company Overview
- 11.4.2 Role of bioMérieux SA in the Middle East Molecular Diagnostics Market
- 11.4.3 Key Competitors of the Company
- 11.4.4 Key Customers of the Company
- 11.4.5 Business Strategies
- 11.4.6 Financials
- 11.4.7 Key Insights about the Financial Health of the Company
- 11.4.8 SWOT Analysis
- 11.5 BD.
- 11.5.1 Company Overview
- 11.5.2 Role of BD. in the Middle East Molecular Diagnostics Market
- 11.5.3 Key Competitors of the Company
- 11.5.4 Key Customers of the Company
- 11.5.5 Business Strategies
- 11.5.6 Financials
- 11.5.7 Key Insights about Financial Health of the Company
- 11.5.8 SWOT Analysis
- 11.6 Babirus Medical Equipment LLC
- 11.6.1 Company Overview
- 11.6.2 Role of Babirus Medical Equipment Trading LLC in the Middle East Molecular Diagnostics Market
- 11.6.3 Key Competitors of the Company
- 11.6.4 Key Customers of the Company
- 11.6.5 Business Strategies
- 11.6.6 SWOT Analysis
- 11.7 Bio-Rad Laboratories, Inc.
- 11.7.1 Company Overview
- 11.7.2 Role of Bio-Rad Laboratories, Inc. in the Middle East Molecular Diagnostics Market
- 11.7.3 Key Competitors of the Company
- 11.7.4 Key Customers of the Company
- 11.7.5 Business Strategies
- 11.7.5.1 Corporate Strategies
- 11.7.6 Financials
- 11.7.7 Key Insights about Financial Health of the Company
- 11.7.8 SWOT Analysis
- 11.8 Danaher.
- 11.8.1 Company Overview
- 11.8.2 Role of Danaher. in the Middle East Molecular Diagnostics Market
- 11.8.3 Key Competitors of the Company
- 11.8.4 Key Customers of the Company
- 11.8.5 Business Strategies
- 11.8.6 Corporate Strategies
- 11.8.7 Financials
- 11.8.8 Key Insights about Financial Health of the Company
- 11.8.9 SWOT Analysis
- 11.9 F. Hoffmann-La Roche Ltd.
- 11.9.1 Company Overview
- 11.9.2 Role of F. Hoffmann-La Roche Ltd. in the Middle East Molecular Diagnostics Market
- 11.9.3 Key Competitors of the Company
- 11.9.4 Key Customers of the Company
- 11.9.5 Business Strategies
- 11.9.6 Corporate Strategies
- 11.9.7 Financials
- 11.9.8 Key Insights about Financial Health of the Company
- 11.9.9 SWOT Analysis
- 11.10 Guardant Health
- 11.10.1 Company Overview
- 11.10.2 Role of Guardant Health in the Middle East Molecular Diagnostics Market
- 11.10.3 Key Competitors of the Company
- 11.10.4 Key Customers of the Company
- 11.10.5 Corporate Strategies
- 11.10.6 Financials
- 11.10.7 Key Insights about Financial Health of the Company
- 1.1.1 SWOT Analysis
- 11.11 Illumina, Inc.
- 11.11.1 Company Overview
- 11.11.2 Role of Illumina, Inc. in the Middle East Molecular Diagnostics Market
- 11.11.3 Key Competitors of the Company
- 11.11.4 Key Customers of the Company
- 11.11.5 Corporate Strategies
- 11.11.6 Financials
- 11.11.7 Key Insights about the Financial Health of the Company
- 11.11.8 SWOT Analysis
- 11.12 QIAGEN N.V.
- 11.12.1 Company Overview
- 11.12.2 Role of QIAGEN N.V. in the Middle East Molecular Diagnostics Market
- 11.12.3 Key Competitors of the Company
- 11.12.4 Key Customers of the Company
- 11.12.5 Corporate Strategies
- 11.12.6 Key Insights about Financial Health of the Company
- 11.12.7 SWOT Analysis
- 11.13 Thermo Fisher Scientific Inc.
- 11.13.1 Company Overview
- 11.13.2 Role of Thermo Fisher Scientific Inc. in the Middle East Molecular Diagnostics Market
- 11.13.3 Key Competitors of the Company
- 11.13.4 Key Customers of the Company
- 11.13.5 Business Strategies
- 11.13.6 Financials
- 11.13.7 Key Insights about Financial Health of the Company
- 11.13.8 SWOT Analysis
- List of Tables
- Table 1: COVID-19 Impact on Middle East Molecular Diagnostics Market
- List of Figures
- Figure 1: Middle East Molecular Diagnostics Market-Market Dynamics
- Figure 2: Share of Key Market Strategies and Developments, January 2017-September 2021
- Figure 3: Middle East Molecular Diagnostics Market Snapshot, $Million, 2020-2031
- Figure 4: Middle East Molecular Diagnostics Market (by Product), $Million, 2020 Vs. 2031
- Figure 5: Middle East Molecular Diagnostics Market (by Technology), $Million, 2020 Vs. 2031
- Figure 6: Middle East Molecular Diagnostics Market (by Application), $Million, 2020 Vs. 2031
- Figure 7: Middle East Molecular Diagnostics Market (by End User), $Million, 2020 Vs. 2031
- Figure 8: Middle East Molecular Diagnostics Market Research Methodology
- Figure 9: Middle East Molecular Diagnostics Market: Segmentation
- Figure 10: Role of Diagnostics in Healthcare
- Figure 11: Evolution of Molecular Diagnostics
- Figure 12: Classification of Molecular Diagnostics
- Figure 13: Year-Wise Analysis of Patents Related to Molecular Diagnostics, January 2019-October 2021
- Figure 14: Share of Key Developments and Strategies, January 2017-September 2021
- Figure 15: Share of Acquisitions (by Company), January 2017-September 2021
- Figure 16: Share of Synergistic Activities (by Company), January 2017-September 2021
- Figure 17: Share of Product Launches and Upgradations (by Company), January 2017-September 2021
- Figure 18: Share of Business Expansion (by Company), July 2017-August 2021
- Figure 19: Middle East Molecular Diagnostics Market - Market Dynamics
- Figure 20: Rate of Cancer Incidence and Death in 2020
- Figure 21: Personalized Care for Cancer Patients
- Figure 22: Impact of COVID-19 on Middle East Molecular Diagnostics Market
- Figure 23: Share of Middle East Molecular Diagnostics Market (by Product), $Million, 2020 and 2031
- Figure 24: Middle East Molecular Diagnostics Market (Systems), $Million, 2020-2031
- Figure 25: General Workflow of a Molecular Diagnostic Kit
- Figure 26: Middle East Molecular Diagnostics Market (Kits and Consumables), $Million, 2020-2031
- Figure 27: Aspects of Software Development
- Figure 28: Middle East Molecular Diagnostics Market (Software and Other Products), $Million, 2020-2031
- Figure 29: Middle East Molecular Diagnostics Market (by Testing Location)
- Figure 30: Share of Middle East Molecular Diagnostics Market (by Testing Location), $Million, 2020 and 2031
- Figure 31: Middle East Molecular Diagnostics Market (Laboratory Testing), $Million, 2020-2031
- Figure 32: Middle East Molecular Diagnostics Market (Point-of-Care Testing), $Million, 2020-2031
- Figure 33: Share of Middle East Molecular Diagnostics Market (by Technology), $Million, 2020 and 2031
- Figure 34: Middle East Molecular Diagnostics Market (Polymerase Chain Reaction), $Million, 2020-2031
- Figure 35: Middle East Molecular Diagnostics Market (Next-Generation Sequencing), $Million, 2020-2031
- Figure 36: Middle East Molecular Diagnostics Market (Isothermal Nucleic Acid Amplification Technology), $Million, 2020-2031
- Figure 37: Middle East Molecular Diagnostics Market (Microarray), $Million, 2020-2031
- Figure 38: Middle East Molecular Diagnostics Market (ISH), $Million, 2020-2031
- Figure 39: Middle East Molecular Diagnostics Market (IHC), $Million, 2020-2031
- Figure 40: Middle East Molecular Diagnostics Market (Other Technologies), $Million, 2020-2031
- Figure 41: Middle East Molecular Diagnostics Market (by Application), $Million, 2020 and 2031
- Figure 42: Middle East Molecular Diagnostics Market (Core Molecular Diagnostics), $Million, 2020-2031
- Figure 43: Middle East Molecular Diagnostics Market (Reproductive Genetics), $Million, 2020-2031
- Figure 44: Middle East Molecular Diagnostics Market (Companion Diagnostics), $Million, 2020-2031
- Figure 45: Middle East Molecular Diagnostics Market (Liquid Biopsy), $Million, 2020-2031
- Figure 46: Middle East Molecular Diagnostics Market (Other Applications), $Million, 2020-2031
- Figure 47: Share of Middle East Molecular Diagnostics Market (by End User), $Million, 2020 and 2031
- Figure 48: Middle East Molecular Diagnostics Market (Hospitals), $Million, 2020-2031
- Figure 49: Middle East Molecular Diagnostics Market (Diagnostic Centers), $Million, 2020-2031
- Figure 50: Middle East Molecular Diagnostics Market (Out-Patient Clinics/General Practitioners), $Million, 2020-2031
- Figure 51: Middle East Molecular Diagnostics Market (Research Laboratories), $Million, 2020-2031
- Figure 52: Middle East Molecular Diagnostics Market (Other End Users), $Million, 2020-2031
- Figure 53: Middle East Molecular Diagnostics Market (by Country), $Million, 2020-2031
- Figure 54: Middle East Molecular Diagnostics Market (by Country), 2021 and 2031
- Figure 55: Kingdom of Saudi Arabia Diagnostics Market $Million, 2020-2031
- Figure 56: Israel Molecular Diagnostics Market, $Million, 2020-2031
- Figure 57: U.A.E. Molecular Diagnostics Market, $Million, 2020-2031
- Figure 58: Egypt Molecular Diagnostics Market, $Million, 2020-2031
- Figure 59: Iran Molecular Diagnostics Market, $Million, 2020-2031
- Figure 60: Qatar Molecular Diagnostics Market, $Million, 2020-2031
- Figure 61: Rest-of-the-Middle East Molecular Diagnostics Market, $Million, 2020-2031
- Figure 62: Total Number of Companies Profiled
- Figure 63: Abbott.: Overall Product Portfolio
- Figure 64: Abbott.: Overall Financials, 2019-2021
- Figure 65: Abbott.: Revenue (by Segment), 2019-2021
- Figure 66: Abbott.: Revenue (by Region), 2019-2021
- Figure 67: Abbott.: R&D Expenditure, 2019-2021
- Figure 68: Abbott.: SWOT Analysis
- Figure 69: Agilent Technologies, Inc.: Overall Product Portfolio
- Figure 70: Agilent Technologies, Inc.: Overall Financials, 2019-2021
- Figure 71: Agilent Technologies, Inc.: Revenue (by Segment), 2019-2021
- Figure 72: Agilent Technologies, Inc.: Revenue (by Region), 2019-2021
- Figure 73: Agilent Technologies, Inc.: R&D Expenditure, 2019-2021
- Figure 74: Agilent Technologies, Inc.: SWOT Analysis
- Figure 75: bioMérieux SA: Product Portfolio
- Figure 76: bioMérieux SA: Overall Financials, $Million, 2019-2021
- Figure 77: bioMérieux SA: Revenue (by Segment), $Million, 2019-2021
- Figure 78: bioMérieux SA: Revenue (by Region), $Million, 2019-2021
- Figure 79: bioMérieux SA: R&D Expenditure, $Million, 2019-2021
- Figure 80: bioMérieux SA: SWOT Analysis
- Figure 81: BD.: Overall Product Portfolio
- Figure 82: BD.: Overall Financials, 2019-2021
- Figure 83: BD.: Revenue (by Segment), 2019-2021
- Figure 84: BD.: Revenue (by Region), 2019-2021
- Figure 85: BD.: R&D Expenditure, 2019-2021
- Figure 86: BD.: SWOT Analysis
- Figure 87: Babirus Medical Equipment Trading LLC: Overall Product Portfolio
- Figure 88: Babirus Medical Equipment Trading LLC: SWOT Analysis
- Figure 89: Bio-Rad Laboratories, Inc.: Overall Product Portfolio
- Figure 90: Bio-Rad Laboratories, Inc.: Overall Financials, 2019-2021
- Figure 91: Bio-Rad Laboratories, Inc.: Revenue (by Segment), 2019-2021
- Figure 92: Bio-Rad Laboratories, Inc.: Revenue (by Region), 2019-2021
- Figure 93: Bio-Rad Laboratories, Inc.: R&D Expenditure, 2019-2021
- Figure 94: Bio-Rad Laboratories, Inc.: SWOT Analysis
- Figure 95: Danaher.: Overall Product Portfolio
- Figure 96: Danaher.: Overall Financials, 2019-2021
- Figure 97: Danaher.: Revenue (by Segment), 2019-2021
- Figure 98: Danaher.: Revenue (by Region), 2019-2021
- Figure 99: Danaher.: R&D Expenditure, 2019-2021
- Figure 100: Danaher.: SWOT Analysis
- Figure 101: F. Hoffmann-La Roche Ltd: Overall Product Portfolio
- Figure 102: F. Hoffmann-La Roche Ltd: Overall Financials, 2019-2021
- Figure 103: F. Hoffmann-La Roche Ltd: Revenue (by Segment), 2019-2021
- Figure 104: F. Hoffmann-La Roche Ltd: Revenue (by Region), 2019-2021
- Figure 105: F. Hoffmann-La Roche Ltd: R&D Expenditure, 2019-2021
- Figure 106: F. Hoffmann-La Roche Ltd: SWOT Analysis
- Figure 107: Guardant Health: Overall Product Portfolio
- Figure 108: Guardant Health: Overall Financials, 2018-2020
- Figure 109: Guardant Health: Revenue (by Segment), 2018-2020
- Figure 110: Guardant Health: R&D Expenditure, 2018-2020
- Figure 111: Guardant Health: SWOT Analysis
- Figure 112: Illumina, Inc.: Product Portfolio
- Figure 113: Illumina, Inc.: Overall Financials, $Million, 2019-2021
- Figure 114: Illumina, Inc.: Revenue (by Segment), $Million, 2019-2021
- Figure 115: Illumina, Inc.: Revenue (by Region), $Million, 2019-2021
- Figure 116: Illumina, Inc.: R&D Expenditure, $Million, 2019-2021
- Figure 117: Illumina, Inc.: SWOT Analysis
- Figure 118: QIAGEN N.V.: Overall Product Portfolio
- Figure 119: QIAGEN N.V.: Overall Financials, 2019-2021
- Figure 120: QIAGEN N.V.: Revenue (by Segment), 2019-2021
- Figure 121: QIAGEN N.V.: Revenue (by Region), 2019-2021
- Figure 122: QIAGEN N.V.: R&D Expenditure, 2019-2021
- Figure 123: QIAGEN N.V.: SWOT Analysis
- Figure 124: Thermo Fisher Scientific Inc.: Overall Product Portfolio
- Figure 125: Thermo Fisher Scientific Inc.: Overall Financials, $Million, 2019-2021
- Figure 126: Thermo Fisher Scientific Inc.: Revenue (by Business Segment), $Million, 2019-2021
- Figure 127: Thermo Fisher Scientific Inc.: Revenue (by Region), $Million, 2019-2021
- Figure 128: Thermo Fisher Scientific Inc.: R&D Expenditure, $Million, 2019-2021
- Figure 129: Thermo Fisher Scientific Inc.: SWOT Analysis
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.